Format

Send to

Choose Destination
Arch Intern Med. 2006 Apr 24;166(8):837-43.

Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials.

Author information

1
Department of Palliative Medicine, University of Bristol, Bristol, England. Colette.reid@bristol.ac.uk

Erratum in

  • Arch Intern Med. 2006 Nov 27;166(21):2387.

Abstract

To evaluate the efficacy and tolerability of oxycodone in cancer-related pain, we conducted a systematic review of randomized controlled trials. Four studies, comparing oral oxycodone with either oral morphine (n = 3) or oral hydromorphone (n = 1), were suitable for meta-analysis. Standardized mean differences in pain scores comparing oxycodone with control groups were pooled using random-effects models. Overall, there was no evidence that mean pain scores differed between oxycodone and control drugs (pooled standardized mean difference, 0.04; 95% confidence interval [CI], -0.29 to 0.36; P = .8; I(2) = 62%). In meta-regression analyses, pain scores were higher for oxycodone compared with morphine (0.20; 95% CI, -0.04 to 0.44) and lower compared with hydromorphone (-0.36; 95% CI, -0.71 to 0.00), although these effect sizes were small. The efficacy and tolerability of oxycodone are similar to morphine, supporting its use as an opioid for cancer-related pain.

PMID:
16636208
DOI:
10.1001/archinte.166.8.837
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center